


Bionime Corporation 2021 Online Investor Conference

Dec 9, 2021




Bionime Group Taiwan



About Us

Established in April 2003, Bionime is specialized in the business of biotechnology and medical testing. The first product line is the Self Monitoring Blood Glucose (SMBG) System. Bionime integrates the top-tier expertise in medical science, chemistry, electronics and precision mechanism to commercialize the patented technology of unique test strip structure.


Today, Bionime operates 4 subsidiaries in major markets, Europe, America, and China. Our products have been highly recognized by outstanding clinical tests and well-known journals internationally and successfully distributed in the worldwide markets. With the support from our customers, we are confident to grow BIONIME the global competitive leadership in the field of SMBG (Self-Monitor Blood Glucose).



Bionime profile

Date of Establishment	April 14, 2003
Stock #	TSEC 4737/ IPO December,2010
Capital	NT\$622 million
Head office	South District, Taichung,Taiwan.
Building	56,227 m ²
Main business	Diabetes Care Industry/Glucose Management System and Services
Foreign subsidiary	Switzerland, China, United States of America , Australia, Malaysia (Brand Business Marketing and Customer Service)

Foreign Subsidiary and Agent



What Products & Services **BIONIME** does Bionime offer?

12% of **Global Health Expenditure** used on **Diabetes care**.

70%-80% of every nation's Diabetes care expenditure used in dealing with **Diabetes complications**. **Glucose Management** is the **only** method for **Prevention**.

Bionime founded in 2003. Focuses on **R&D, Design, Manufacture** and **Marketing of Blood Glucose Management Systems**.

Products **encompass** all **3 main** medical devices for Blood Glucose Management.

Using **IOT** to **unite** the 3 components into an **ecosystem**.



Bionime Products **Encompasses & Unites** All **3 major medical device** for Glucose Management

2003 Start-up
Product

BGM

Blood Glucose Monitor

Bionime's **All-new Product** R&D starting
2010, 2016


CGM

Continuous Glucose Monitor

Patch Pump

Disposable Insulin Delivery

2021 MeetingTOPIC



Bionime uses the **Rightest Care System** developed in-house to **unite** Glucose Management's **3 main** medical device into a **smart IOT Ecosystem**

Rightest Care Eco-System

以使用者為中心的糖尿病服務生態系

Patient Centric Diabetes Service Ecosystem




Financial report

UNIT: NT Thousand dollars

NT\$ (M)	2017	2018	2019	2020	2021.Q3
Net Revenue	1,820	2,007	2,173	1,669	1,372
Gross Profit	796	917	948	749	586
Gross Margin(%)	44%	46%	44%	45%	43%
Operation Profit	249	241	156	21	47
Operation Margin (%)	14%	12%	7%	1%	3%
Net income	150	128	107	64	58
Net Margin(%)	8%	6%	5%	4%	4%
EPS (NT\$)	2.52	2.23	1.85	1.06	0.93


Sales Region

BIONINE



product sales

BIONINE



Dividend

BIONINE

Unit: NTD

Year	2016	2017	2018	2019	2020
EPS	2.82	2.52	2.23	1.85	1.06
Cash dividend	2.54	-	2.0	1.51	0.86
Capital reserve	1.26	4.14	-	0.49	1.21
Total	3.8	4.14	2.0	2.0	2.1

Q & A

Thank you

BIONIME

BIONIME CORPORATION

華廣生技股份有限公司

No.100, Sec. 2, Daqing St., South Dist.,
Taichung City 40242, Taiwan (R.O.C.)

40242 台中市南區大慶街二段100號

P. +886 (04) 2369-2388

F. +886 (04) 2261-7586

www.bionime.com

